Learn and review a variety of critical dermatological diagnosis factors, treatment options, and effective protocols and practices through our interactive challenge quizzes.
Answer: A
Explanation: According to the AJCC 8th edition, primary melanoma tumor thickness is to be measured to the nearest 0.1 mm, not to the nearest 0.01 as specified in prior editions.
For more information, please see Gershenwald, Jeffrey E., et al. "Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual." CA: a cancer journal for clinicians 67.6 (2017): 472-492
Answer: D
Explanation: According to current guidelines, tumor thickness (as determined by the AJCC criteria) and SNLB are the standards in melanoma risk stratification. In addition, gene expression profiling can provide prognostic information that can aid standard clinical and pathological staging
For more information, please see, Gershenwald, Jeffrey E., et al. "Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual." CA: a cancer journal for clinicians 67.6 (2017): 472-492
Answer: B
Explanation: According to the NCCN guidelines, wide excision is recommended for in situ melanomas; SLN biopsy is recommended for local melanoma, and systemic therapy is recommended in later stages or metastatic melanoma.
For more information, please see, Coit, Daniel G., et al. "Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology." Journal of the National Comprehensive Cancer Network 14.4 (2016): 450-473
Explanation: According to the latest consensus statement on the adverse events of cancer immunotherapy, immune-checkpoint therapy can have serious immediate dermatologic adverse events, including (but not limited to) dermatitis, bullous dermatoses, and vitiligo
For more information, please see, Brahmer, Julie R., et al. "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline." Journal of Clinical Oncology36.17 (2018): 1714-1768.
Explanation: In patients with early melanoma or when melanoma is suspected, studies have shown that using gene expression assays is an efficacious method for non-invasive risk stratification. As such, before offering further imaging or SNLB testing, a non-invasive test can help in deciding which patients are appropriate candidates for further diagnostic or prognostic standard of care testing.
For more information, please see, le Roux, Carel, et al. Zager, Jonathan S., et al. "Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients." BMC cancer 18.1 (2018): 130.
